Your session is about to expire
← Back to Search
Chemotherapy + Targeted Therapy for Breast Cancer
Study Summary
This trial is testing whether a combination of drugs is effective and has few side effects when given before surgery to people with HER2-positive or HER2-negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious heart condition, such as heart failure or angina.I am not pregnant or nursing and agree to use contraception during and for a month after treatment.- Your blood counts need to be in a certain range.
- Your liver and kidney function tests need to be within normal limits.
- Women capable of getting pregnant need to have a negative pregnancy test within 14 days before starting the trial.My blood counts are low, increasing my risk for severe bleeding.I am a woman aged 18 or older.I know my cancer's HER2 status.My heart function is normal, confirmed by a test within the last 3 months.I am a male.I have wounds that are not fully healed.My breast cancer is confirmed by tissue analysis and can be in one or both breasts.I am able to get out of my bed or chair and move around.I am currently experiencing significant bleeding.My breast cancer is of the inflammatory type.My tumor is at least 1 cm big or I have cancer in my lymph nodes.I have nerve damage that limits my daily activities.My cancer has spread to distant parts of my body.
- Group 1: Carboplatin+Paclitaxel+Bevacizumab (HER2-)
- Group 2: Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please tell me what other research has been conducted on Paclitaxel?
"As of right now, there are 1656 ongoing studies involving Paclitaxel. Of these, 442 trials have reached Phase 3 status. Most investigations into Paclitaxel's efficacy are taking place in Seattle, but there are 86768 total trial locations worldwide."
What is the most common use for Paclitaxel?
"While cyclophosphamide is often treated with Paclitaxel, this medication can also be used to effectively manage other conditions like lymphoma, non-hodgkin, recurrent cervical cancer, and locally advanced non-small cell lung cancer."
Are people still being signed up for this research project?
"The clinicaltrials.gov website provides information that this study is open for enrollment and currently recruiting patients. This particular trial was posted on April 1st, 2015 with the most recent update being on April 15th, 2021. The research team is seeking a total of 120 individuals from one location to participate in this study."
Is there a limit to how many people can join this clinical trial?
"Yes, the information on clinicaltrials.gov confirms that this trial is currently searching for patients. The original posting date was April 1st, 2015 and the most recent update was on April 15th, 2021. The study plans to enroll 120 patients at a single location."
Has Paclitaxel been federally sanctioned for clinical use?
"Paclitaxel is a Phase 2 medication, meaning that while there is some evidence supporting its safety, there is no data to suggest that it is effective. We rated Paclitaxel's safety as a 2."
Share this study with friends
Copy Link
Messenger